Dominari Holdings Inc. (DOMH)
| Market Cap | 21.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.77M |
| Shares Out | 5.49M |
| EPS (ttm) | -3.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,369 |
| Open | 3.96 |
| Previous Close | 3.83 |
| Day's Range | 3.80 - 3.99 |
| 52-Week Range | 3.02 - 10.20 |
| Beta | 0.92 |
| Analysts | n/a |
| Price Target | 16.32 (+318.46%) |
| Earnings Date | Mar 27, 2023 |
About DOMH
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebo... [Read more]
Financial Performance
Financial StatementsNews
Dominari Holdings Provides Update on Share Repurchase Program
NEW YORK , Jan. 27, 2023 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase ...